Literature DB >> 21594779

Nasal potential difference measurements to assess CFTR ion channel activity.

Steven M Rowe1, John Paul Clancy, Michael Wilschanski.   

Abstract

The Nasal potential difference measurement is used to measure the voltage across the nasal epithelium, which results from transepithelial ion transport and reflects in part CFTR function. The electrophysiologic abnormality in cystic fibrosis was first described 30 years ago and correlates with features of the CF phenotype. NPD measurement is an important in vivo research and diagnostic tool, and is used to assess the efficacy of new treatments such as gene therapy and ion transport modulators. This chapter will elaborate on the electrophysiological principles behind the test, the equipment required, the methods, and the analysis of the data.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21594779      PMCID: PMC3760477          DOI: 10.1007/978-1-61779-117-8_6

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  29 in total

1.  Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution.

Authors:  Michael W Konstan; Pamela B Davis; Jeffrey S Wagener; Kathleen A Hilliard; Robert C Stern; Laura J H Milgram; Tomasz H Kowalczyk; Susannah L Hyatt; Tamara L Fink; Christopher R Gedeon; Sharon M Oette; Jennifer M Payne; Osman Muhammad; Assem G Ziady; Robert C Moen; Mark J Cooper
Journal:  Hum Gene Ther       Date:  2004-12       Impact factor: 5.695

2.  Cystic fibrosis.

Authors:  Steven M Rowe; Stacey Miller; Eric J Sorscher
Journal:  N Engl J Med       Date:  2005-05-12       Impact factor: 91.245

3.  Potential difference measurements in the lower airway of children with and without cystic fibrosis.

Authors:  Jane C Davies; Michael Davies; Donna McShane; Stephen Smith; Sharon Chadwick; Adam Jaffe; Raymond Farley; Louise Collins; Andrew Bush; Michael Scallon; John Pepper; Duncan M Geddes; Eric W F W Alton
Journal:  Am J Respir Crit Care Med       Date:  2005-01-07       Impact factor: 21.405

Review 4.  Macromolecular complexes of cystic fibrosis transmembrane conductance regulator and its interacting partners.

Authors:  Chunying Li; Anjaparavanda P Naren
Journal:  Pharmacol Ther       Date:  2005-06-02       Impact factor: 12.310

Review 5.  Cystic fibrosis: terminology and diagnostic algorithms.

Authors:  K De Boeck; M Wilschanski; C Castellani; C Taylor; H Cuppens; J Dodge; M Sinaasappel
Journal:  Thorax       Date:  2005-12-29       Impact factor: 9.139

6.  Nasal airway ion transport is linked to the cystic fibrosis phenotype in adult patients.

Authors:  I Fajac; D Hubert; D Guillemot; I Honoré; T Bienvenu; F Volter; J Dall'Ava-Santucci; D J Dusser
Journal:  Thorax       Date:  2004-11       Impact factor: 9.139

7.  Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials.

Authors:  Michael Wilschanski; Annie Dupuis; Lynda Ellis; Keith Jarvi; Julian Zielenski; Elizabeth Tullis; Sheelagh Martin; Mary Corey; Lap-Chee Tsui; Peter Durie
Journal:  Am J Respir Crit Care Med       Date:  2006-07-13       Impact factor: 21.405

Review 8.  Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials.

Authors:  Steven M Rowe; Frank Accurso; John P Clancy
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

9.  No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.

Authors:  John P Clancy; Steven M Rowe; Zsuzsa Bebok; Moira L Aitken; Ron Gibson; Pam Zeitlin; Pierre Berclaz; Rick Moss; Michael R Knowles; Robert A Oster; Nicole Mayer-Hamblett; Bonnie Ramsey
Journal:  Am J Respir Cell Mol Biol       Date:  2007-03-08       Impact factor: 6.914

10.  In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study.

Authors:  Isabelle Sermet-Gaudelus; Michel Renouil; Anne Fajac; Laure Bidou; Bastien Parbaille; Sébastien Pierrot; Nolwen Davy; Elise Bismuth; Philippe Reinert; Gérard Lenoir; Jean François Lesure; Jean Pierre Rousset; Aleksander Edelman
Journal:  BMC Med       Date:  2007-03-29       Impact factor: 8.775

View more
  31 in total

1.  Repurposing tromethamine as inhaled therapy to treat CF airway disease.

Authors:  Mahmoud H Abou Alaiwa; Janice L Launspach; Kelsey A Sheets; Jade A Rivera; Nicholas D Gansemer; Peter J Taft; Peter S Thorne; Michael J Welsh; David A Stoltz; Joseph Zabner
Journal:  JCI Insight       Date:  2016-06-02

2.  Positioning of extracellular loop 1 affects pore gating of the cystic fibrosis transmembrane conductance regulator.

Authors:  Daniel T Infield; Guiying Cui; Christopher Kuang; Nael A McCarty
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-12-18       Impact factor: 5.464

3.  Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis.

Authors:  Steven M Rowe; Ginger Reeves; Heather Hathorne; G Martin Solomon; Smita Abbi; Didier Renard; Ruth Lock; Ping Zhou; Henry Danahay; John P Clancy; David A Waltz
Journal:  Chest       Date:  2013-07       Impact factor: 9.410

4.  Herbal dry extract BNO 1011 improves clinical and mucociliary parameters in a rabbit model of chronic rhinosinusitis.

Authors:  Do-Yeon Cho; Daniel Skinner; Calvin Mackey; Harold B Lampkin; Jeffrey Brent Elder; Dong Jin Lim; Shaoyan Zhang; Justin McCormick; Guillermo J Tearney; Steven M Rowe; Bradford A Woodworth
Journal:  Int Forum Allergy Rhinol       Date:  2019-01-18       Impact factor: 3.858

5.  Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis.

Authors:  Ema Robinson; Kelvin D MacDonald; Kai Slaughter; Madison McKinney; Siddharth Patel; Conroy Sun; Gaurav Sahay
Journal:  Mol Ther       Date:  2018-06-15       Impact factor: 11.454

6.  A multiple reader scoring system for Nasal Potential Difference parameters.

Authors:  George M Solomon; Bo Liu; Isabelle Sermet-Gaudelus; Isabelle Fajac; Michael Wilschanski; Francois Vermeulen; Steven M Rowe
Journal:  J Cyst Fibros       Date:  2017-04-29       Impact factor: 5.482

7.  Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD.

Authors:  Mark T Dransfield; Andrew M Wilhelm; Brian Flanagan; Clifford Courville; Sherry L Tidwell; S Vamsee Raju; Amit Gaggar; Chad Steele; Li Ping Tang; Bo Liu; Steven M Rowe
Journal:  Chest       Date:  2013-08       Impact factor: 9.410

8.  Optical Nanosensors for in vivo Physiological Chloride Detection for Monitoring Cystic Fibrosis Treatment.

Authors:  Wenjun Di; Heather A Clark
Journal:  Anal Methods       Date:  2020-02-26       Impact factor: 2.896

9.  Influenza-mediated reduction of lung epithelial ion channel activity leads to dysregulated pulmonary fluid homeostasis.

Authors:  Jeffrey D Brand; Ahmed Lazrak; John E Trombley; Ren-Jay Shei; A Timothy Adewale; Jennifer L Tipper; Zhihong Yu; Amit R Ashtekar; Steven M Rowe; Sadis Matalon; Kevin S Harrod
Journal:  JCI Insight       Date:  2018-10-18

10.  Amphotericin B induces epithelial voltage responses in people with cystic fibrosis.

Authors:  Rajeev S Chorghade; Bo Ram Kim; Janice L Launspach; Philip H Karp; Michael J Welsh; Martin D Burke
Journal:  J Cyst Fibros       Date:  2020-12-08       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.